We are delighted to announce that Dr Matthew Wintle has joined the Diabetes Trials Unit (DTU) as a Clinical Researcher.
Matthew has joined us from Amylin Pharmaceuticals in California, where he was Global Medical Director. During his time at Amylin he worked across the research, development and commercialisation pathway, helping to advance four first-in-class therapies for patients with diabetes and rare metabolic diseases.
Within the DTU, Matthew will be the Acting Clinical Lead for the Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT), and will work on early phase studies with the Translational Research Group (TRG) to evaluate innovative technologies.
We wish him every success in his new role.